CYCLOSET
Peakbromocriptine mesylate
NDAORALTABLET
Approved
May 2009
Lifecycle
Peak
Competitive Pressure
0/100
Mechanism of Action
mesylate, a sympatholytic, dopamine D2 receptor agonist. In patients with type 2 diabetes, timed morning administration of CYCLOSET is associated with increased insulin sensitivity and glucose disposal and reduced fasting and postprandial hyperglycemia throughout the meals of the day without…
Indications (3)
Loss of Exclusivity
LOE Date
Apr 30, 2032
74 months away
Patent Expiry
Apr 30, 2032